Navigation Links
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
Date:5/3/2012

ations regarding conversion to accrual accounting for diagnostics revenue and the timing thereof, expectations regarding future gross margin fluctuation on a quarterly basis, the use of proceeds from Sequenom's underwritten public offering completed during the first quarter, growing demand for Sequenom CMM's testing services, annualized run rates for the MaterniT21 PLUS test requests, Sequenom's goals for MaterniT21 PLUS LDTs billed for 2012, Sequenom's goal to build on positive momentum, and plans and goals to expand and meet growing demand and deliver on its objective to provide high quality testing services to physician customers nationwide, growing commercial interest and demand for Sequenom CMM's testing services, Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, dedication to the development and commercialization of laboratory developed tests, and changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation, including patent litigation, and other risks detailed from time to time in Sequenom, Inc.'s most recent Annual Report on Securities and Exchange Commission Form 10-K and other d
'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sequenom, Inc. Announces Date of Third Quarter 2011 Financial Results and Conference Call
2. Neuland Labs Reports Financial Results For Fiscal Year 2012
3. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
4. GP Strategies Reports Strong First Quarter 2012 EPS of $0.23
5. Cardinal Health Reports Third-Quarter Results
6. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Neurocrine Biosciences Reports First Quarter 2012 Results
9. CVS Caremark Reports Record First Quarter Results
10. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
11. Thoratec Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... PARIS, June  24, 2011 Sanofi (EURONEXT: SAN and ... four studies  of its once-daily GLP-1 receptor agonist Lyxumia® ... data that demonstrates positive results in type 2 diabetes ...  basal insulin. These data are being presented or published ...
... Global Technologies, Ltd. (GTLL), announced today that it has executed ... Orchard, Inc. GTLL will acquire 100% of ... entity.  All current management, board, and officers will concurrently resign ... are expected to be completed within 21 days. ...
Cached Medicine Technology:Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 2Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 3Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 4Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 5Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 6Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 7Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association's 71st Annual Scientific Sessions 8Global Technologies, Ltd. Announces LOI to Acquire and Merge with Oxygen Orchard, Inc. 2
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... guidelines were issued today by the National Institute for Health ... Mental Health,// on the identification, treatment and management of obsessive-compulsive ... adults. , ... all ages, and commonly starts in childhood or adolescence, and ...
... calcium from food tend to gain more bone mass than ... team reports.// ,The team conducted the study to learn ... rapid-growth period of puberty in which 60 percent of the ... , ,The study, published in the November issue of ...
... of breast-feeding is associated with reduction in risk of ... studies have already provided evidence for improved insulin sensitivity ... their counterparts. ,The study is the first of ... lactation and Type 2 diabetes. More than 1,57,003 parous ...
... the life span of people who are suffering from the ... of death from cancer //and is one of the most ... cancer vaccine trial show that it improved the survival rates ... diagnosis to 88 percent." It was also found that the ...
... India has the potential to be the healthcare crisis ... billion from medical tourism, experts say.// ,Speaking at ... Industry (CII) and the Indian Health Care Foundation (IHCF), ... healthcare and facilitate public-private partnership to support quality healthcare ...
... A British grandmother from Wolverhampton has returned to the UK ... lower cost, yet another testimony to India’s burgeoning medical tourism.// ... to have the surgery on the National Health Service (NHS). ... which meant a further six months of chronic pain., ...
Cached Medicine News:Health News:Calcium From Food Better Than From Supplements 2Health News:Breastfeeding To Reduce Risk Of Type 2 Diabetes 2Health News:India Can Manage World’s Healthcare Crisis By 202 2Health News:British Grandmother has timely bypass surgery in India 2
For canalicular laceration involving external 2/3 of one canaliculus. Medical grade silicone. Box of 3, sterile. Note: For safe and proper insertion of the punctum plug above, we recommend the use of...
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
For proper plug sizing....
Contour Design Eyelid Implants....
Medicine Products: